Related Experiment Video
Updated: May 4, 2026

Localization, Identification, and Excision of Murine Adipose Depots
Published on: December 4, 2014
Adipose Depot Changes and Associated Metabolic Risk in the Longitudinal Health Influences of Puberty Study
Catherine C Cohen1, Jaime M Moore2,3, Samantha Bothwell2
1Lifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Objective:
To assess longitudinal changes in abdominal subcutaneous and visceral adipose tissue (SAT and VAT), hepatic fat fraction (HFF) and pancreatic fat fraction (PFF) across puberty in youth with/without obesity and examine associations with cardiometabolic risk markers.
Methods:
Within the Health Influences of Puberty (HIP) cohort, we included 19 participants (53% female, 37% obesity) who completed magnetic resonance imaging (MRI) at early (Tanner 2/3) and late (Tanner 4/5) puberty to assess abdominal SAT and VAT areas (cm2), HFF (%) and PFF (%). Cardiometabolic markers included glucose/insulin measures assessed by intravenous glucose tolerance test, fasting lipid panel and adipokines.
Results:
From early to late puberty, among youth with obesity, median (interquartile range) abdominal SAT increased 83.1cm2 (43.4) and, among youth without obesity, VAT/SAT ratio decreased -0.08 (0.08) and HFF increased 0.6% (0.5). In linear mixed models of adipose depots in early puberty and metabolic markers measured twice during puberty, adjusted for BMI group, abdominal SAT was positively associated with leptin β (95% confidence interval): 1.05 (0.35, 1.74), and VAT was positively associated with triglycerides 0.32 (0.02, 0.61) and high-sensitivity c-reactive protein (hsCRP) 1.40 (0.31, 2.49), while HFF was inversely associated with insulin sensitivity 0.32 (-0.58, -0.07) and PFF was inversely associated with adiponectin 0.23 (-0.42, -0.04) (all p < 0.05).
Conclusion:
In this small sample, abdominal and ectopic fat depots in early puberty were uniquely associated with alterations in cardiometabolic risk markers during puberty.
Trial Registration:
ClinicalTrials.gov identifier: NCT01775813.
Related Concept Videos
Hypodermis
Obesity
Signs of Puberty
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Type II Diabetes I: Introduction

